Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Anti-CD19CAR-CD28-CD3zeta-EGFRt T-cells |
Trade Name | |
Synonyms | Autologous CD19 CAR+ EGFRt + CD4+ and CD8+ T cells |
Drug Descriptions |
Anti-CD19CAR-CD28-CD3zeta-EGFRt T-cells comprise CD4- and CD8-positive autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) containing an anti-CD19 fragment linked to the CD28 and CD3zeta signaling domains and a truncated human epidermal growth factor receptor (EGFRt), which potentially induce cytotoxicity against CD19-expressing tumor cells and antitumor activity (PMID: 28408462, NCI Drug Dictionary). |
DrugClasses | CD19 Immune Cell Therapy 62 |
CAS Registry Number | NA |
NCIT ID | C137866 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Anti-CD19CAR-CD28-CD3zeta-EGFRt T-cells | Anti-CD19CAR-CD28-CD3zeta-EGFRt T-cells | 0 | 3 |
Anti-CD19CAR-CD28-CD3zeta-EGFRt T-cells + Iomab-B | Anti-CD19CAR-CD28-CD3zeta-EGFRt T-cells Iomab-B | 0 | 1 |